WO2005104766A3 - Injection d'un milieu conditionne derive de la moelle osseuse pour favoriser l'angiogenese - Google Patents

Injection d'un milieu conditionne derive de la moelle osseuse pour favoriser l'angiogenese Download PDF

Info

Publication number
WO2005104766A3
WO2005104766A3 PCT/US2005/014513 US2005014513W WO2005104766A3 WO 2005104766 A3 WO2005104766 A3 WO 2005104766A3 US 2005014513 W US2005014513 W US 2005014513W WO 2005104766 A3 WO2005104766 A3 WO 2005104766A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone marrow
cells
conditioned medium
early attaching
attaching cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/014513
Other languages
English (en)
Other versions
WO2005104766A2 (fr
Inventor
Ran Kornowski
Shmuel Fuchs
Stephen Epstein
Martin B Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myocardial Therapeutics Inc
Original Assignee
Myocardial Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myocardial Therapeutics Inc filed Critical Myocardial Therapeutics Inc
Publication of WO2005104766A2 publication Critical patent/WO2005104766A2/fr
Publication of WO2005104766A3 publication Critical patent/WO2005104766A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des procédés permettant de favoriser la formation d'un apport de sang collatéral au niveau d'un site ischémique dans un tissu, par culture de cellules à fixation précoce dérivées de la croissance de moelle osseuse obtenue par aspiration in vitro, collecte des cellules à fixation précoce produites par la culture de moelle osseuse et injection du milieu conditionné produit par la culture de ces cellules à fixation précoce dans un site ischémique du coeur ou d'un membre. Les cellules à fixation précoce préférées pouvant être utilisées dans les procédés de cette invention sont des cellules stromales dérivées de la moelle. Toute moelle osseuse d'un donneur peut être utilisée pour la préparation du milieu conditionné. Eventuellement, les cellules à fixation précoce peuvent être transfectées au moyen d'un transgène favorisant l'angiogenèse et codant le facteur 1 alpha induisant l'hypoxie, un facteur de croissance des fibroblastes et/ou une monoxyde d'azote-synthase. L'invention se rapporte également à des milieux conditionnés contenant des cytokines angiogéniques produites à partir de ces cellules et destinées à être injectées dans un tissu, par exemple dans le coeur ou un muscle de membre périphérique, nécessitant la formation d'un apport de sang collatéral.
PCT/US2005/014513 2004-04-28 2005-04-27 Injection d'un milieu conditionne derive de la moelle osseuse pour favoriser l'angiogenese Ceased WO2005104766A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56633204P 2004-04-28 2004-04-28
US60/566,332 2004-04-28

Publications (2)

Publication Number Publication Date
WO2005104766A2 WO2005104766A2 (fr) 2005-11-10
WO2005104766A3 true WO2005104766A3 (fr) 2006-01-12

Family

ID=35242168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014513 Ceased WO2005104766A2 (fr) 2004-04-28 2005-04-27 Injection d'un milieu conditionne derive de la moelle osseuse pour favoriser l'angiogenese

Country Status (1)

Country Link
WO (1) WO2005104766A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530415B2 (en) 2008-01-30 2013-09-10 Histogen, Inc. Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions
US8535913B2 (en) 2008-01-30 2013-09-17 Histogen, Inc. Soluble composition for promoting hair growth produced by hypoxic culture of fibroblasts cells
WO2009097559A1 (fr) * 2008-01-30 2009-08-06 Histogen, Inc. Compositions de matrice extracellulaires
US8524494B2 (en) 2008-01-30 2013-09-03 Histogen, Inc. Low oxygen tension and BFGF generates a multipotent stem cell from a fibroblast in vitro
KR101610985B1 (ko) * 2008-11-14 2016-04-08 히스토젠, 인코포레이티드 암 치료를 위한 세포외 기질 조성물
HRP20180594T1 (hr) * 2009-07-10 2018-08-10 Histogen, Inc. Pripravci od kondicioniranog medija i izvanstaničnog matriksa iz stanica uzgajanih u hipoksičnim uvjetima
EP2612907A1 (fr) * 2012-01-05 2013-07-10 Taipei Veterans General Hospital Préparation de transplant cellulaire

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARMELIET P. ET AL.: "Fibroblast Growth Factor-1stimulates branching and survival of myocardial arteries: A goal for therapeutics angiogenesis.", CIRC. RES., vol. 87, 2000, pages 176 - 178 *
ISNER ET AL.: "Therapeutic angiogenesis.Frontiers Biosc.", BIOSC., vol. 3, 5 May 1998 (1998-05-05), pages 49 - 69 *
IWAGURO ET AL.: "Circulation.Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration.", CIRCULATION, vol. 105, no. 6, 12 February 2002 (2002-02-12), pages 733 - 738, XP008107547, DOI: doi:10.1161/hc0602.103673 *

Also Published As

Publication number Publication date
WO2005104766A2 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
Arora et al. Banking stem cells from human exfoliated deciduous teeth (SHED): saving for the future
WO2005007811A3 (fr) Injection de cellules et de fluides derives de ma moelle osseuse pour angiogenese
TW200712208A (en) Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
ES2300320T3 (es) Celulas madre pluripotentes generadas a partir de celulas del estroma derivadas de tejido adiposo y sus usos.
WO2002076285A3 (fr) Composition et methodes de production de tissus biologiques et de constructions tissulaires
WO2007030811A3 (fr) Methodes et compositions de genie tissulaire
WO2006081190A3 (fr) Compositions et methodes de traitement de troubles cardiaques
DK1235536T3 (da) Medicinsk anordning, der omfatter en syntetisk overflade med nukleinsyre til in vivoinduktion af en endothelisering af anordningen
AU1615599A (en) Differentiation of adipose stromal cells into osteoblasts and uses thereof
WO2005007799A3 (fr) Procedes de multiplication ex-vivo de cellules souches / progenitrices
WO2004096975A3 (fr) Appareil et procedes pour l'amplification du nombre de cellules sanguines souche
DE60229848D1 (de) - und organtransplantationen und unterdrückt apoptose
EP2338982A3 (fr) Cellules isolées de cordon ombilical post-partum, méthodes pour leur préparation et leur utilisation.
JP2005521405A5 (fr)
WO2003013239A3 (fr) Procede de devitalisation d'organes naturels et / ou de preparation de matrices extracellulaires pour l'ingenierie tissulaire
WO2005047491A3 (fr) Methodes d'utilisation de cellules de c-kit+ mobilisees par g-cff pour produire des grappes de cellules semblables a un corps embryoide pour la reparation tissulaire et le traitement de la myopathie cardiaque
WO2001007568A3 (fr) Cellules musculaires et leur utilisation dans la reparation cardiaque
WO2004010959A3 (fr) Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires faisant intervenir ces cellules souches
WO2002086073A3 (fr) Generation de tissu differencie a partir de cellules souches embryonnaires generees par transfert nucleaire et methodes d'utilisation
ATE444078T1 (de) Menschliches wachstumshormon zur stimulierung der mobilisierung pluripotenter hämapoietischer stammzellen
WO2005104766A3 (fr) Injection d'un milieu conditionne derive de la moelle osseuse pour favoriser l'angiogenese
CN106074605A (zh) 一种修复皮肤溃疡的组合物及其制备方法
CN109735491A (zh) 一种可扩增造血干细胞的无血清培养基及其制备方法
EP2662439A1 (fr) Traitement de l'ischémie au moyen de cellules souches
EP1702979A3 (fr) Culture amelioree et utilisations de keratinocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 23.03.2007)

122 Ep: pct application non-entry in european phase

Ref document number: 05739992

Country of ref document: EP

Kind code of ref document: A2